Ignite Creation Date:
2024-05-05 @ 10:17 AM
Last Modification Date:
2024-10-26 @ 9:03 AM
Study NCT ID:
NCT00002372
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
1999-11-02
Brief Title:
A Study of 141W94 in Combination With Other Anti-HIV Drugs
Sponsor:
Glaxo Wellcome
Organization:
NIH AIDS Clinical Trials Information Service
Study Overview
Official Title:
A Phase III Screening Trial to Identify Potential Partner Compounds to Use in Combination With 141W94
Status:
COMPLETED
Status Verified Date:
1998-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To determine the steady-state pharmacokinetics of 141W94 in combination with saquinavir indinavir and nelfinavir after multiple oral dosing To determine the steady-state pharmacokinetics of saquinavir indinavir and nelfinavir in combination with 141W94 after multiple oral dosing To assess the safety and tolerability of multiple doses of 141W94 when combined with saquinavir indinavir and nelfinavir
Detailed Description:
Patients will be randomized to receive open label 141W94 in combination with saquinavir indinavir and nelfinavir The randomized phase will be preceded by a single dose pharmacokinetic interaction study of 141W94 and indinavir in 12 patients Data from this single dose investigation will be used to determine the dose of indinavir to be used in the randomized phase
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: